Search results
Results From The WOW.Com Content Network
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
The incredible power of dividends. AbbVie is among an elite group of companies known as Dividend Kings, ... Since 2013, AbbVie's stock price has lagged the pace of the Nasdaq Composite. ABBV Chart.
The company's five-year dividend growth rate of 6.1% compares favorably with its peer average of 4.45%, underscoring AbbVie's historical commitment to sizable and regular dividend increases ...
AbbVie continues to recover from one of the biggest patent cliffs in the pharmaceutical industry's history. Last year, its immunology drug Humira, the top-selling medicine of all time, lost patent ...
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
For reference, AbbVie's trailing 12-month revenue was $55.3 billion, so the growth of Skyrizi and Rinvoq represents a major addition to the top line that'll likely drive the stock upwards for ...
This is the category for the components of the S&P 500 Dividend Aristocrats. Pages in category "Companies in the S&P 500 Dividend Aristocrats" The following 63 pages are in this category, out of 63 total.
The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005.